The natural history, prognosis and management of gastrinomas and other malignant pancreatic endocrine tumors (PET's) in patients without (sporadic disease) or with multiple endocrine neoplasia-type 1 (MEN1) is largely based on antedotal reports and small series. Gastrinomas are the most common symptomatic, malignant PET in patients with or without MEN1 and sufficient numbers of these patients have been entered into our protocols to allow systematic assessment. Studies are now underway, evaluating the natural history of these tumors including the presentation and initial diagnosis, definition of factors determining prognosis and improved methods to diagnose these tumors especially in patients with MEN1. Our studies have identified a cohort of 25% of patients in whom the gastrinomas have aggressive growth. Prospective studies assesssing serum gastrin or chromogranin A show they do not predict growth and serial imaging studies are needed. Molecular studies of gastrinomas of patients with or without aggressive tumors demonstrate alterations in the HER2/neu gene, loss of heterozgosity at 1q and overexpression of the EGF and HGF receptors occur in these tumors and their presence correlates with the aggressive growth. Surgical studies completed during the year support a role for aggressive resection in patients with advanced, aggressive disease. Surgical studies also provide strong support that gastrinomas can arise in lymph nodes and therefore they should be aggressively removed at surgery. The possible side-effects of longterm acid secretory control as well as long term hypergastrinemia are being examined including effects on vitamin B-12 and iron absorption as well as the development of gastric carcinoids and methods to identify these. Lastly, prospective studies on patients with ZES and MEN1 demonstrate male patients may develop thymic carcinoids which are extremely aggressive tumors. Their pathogenesis remains unknown because they lack 11q13 LOH which is usually found in most tumors which develop in patients with MEN1.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK053200-12
Application #
6810464
Study Section
(DDB)
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2003
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Metz, David C; Cadiot, Guillaume; Poitras, Pierre et al. (2017) Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 4:167-185
Ito, Tetsuhide; Igarashi, Hisato; Uehara, Hirotsugu et al. (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92:135-81
Metz, David C; Jensen, Robert T (2008) Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors. Gastroenterology :
Norton, Jeffrey A; Venzon, David J; Berna, Marc J et al. (2008) Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 247:501-10
Long, Scott H; Berna, Marc J; Thill, Michelle et al. (2007) Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab 92:4394-402
Norton, Jeffrey A; Jensen, Robert T (2007) Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 205:S34-7
Berna, Marc J; Hoffmann, K Martin; Serrano, Jose et al. (2006) Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85:295-330
Norton, Jeffrey A; Fang, Tony D; Jensen, Robert T (2006) Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw 4:148-53
Jensen, Robert T (2006) Pancreatic neuroendocrine tumors: overview of recent advances and diagnosis. J Gastrointest Surg 10:324-6
Berna, Marc J; Hoffmann, K Martin; Long, Scott H et al. (2006) Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new Medicine (Baltimore) 85:331-64

Showing the most recent 10 out of 35 publications